Strattera (atomoxetine)

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

ADHD NOS

Conditions

ADHD NOS

Trial Timeline

Dec 1, 2003 → Jul 1, 2008

About Strattera (atomoxetine)

Strattera (atomoxetine) is a approved stage product being developed by Eli Lilly for ADHD NOS. The current trial status is completed. This product is registered under clinical trial identifier NCT00181766. Target conditions include ADHD NOS.

What happened to similar drugs?

9 of 20 similar drugs in ADHD NOS were approved

Approved (9) Terminated (3) Active (10)
atomoxetineEli LillyApproved
Atomoxetine + placeboEli LillyApproved
atomoxetine (Strattera)Eli LillyApproved
🔄dasotraline + PlaceboSumitomo PharmaPhase 3
🔄dasotraline 4mgSumitomo PharmaPhase 3
🔄Focalin XRNovartisPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00181766ApprovedCompleted

Competing Products

20 competing products in ADHD NOS

See all competitors